Ranjit Manchanda MBBS, MD, MRCOG, PhD
Ranjit Manchanda is a Clinical Senior Lecturer at Barts Cancer Institute, QMUL, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital.
Ranjit’s research interests are focused around population-based germline testing, mainstreaming and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention. He has a keen research interest in health economic issues related to his areas of research. He is the Principal Investigator on the PROTECTOR trial, PROMISE Pilot study, GCaPPS trial and SIGNPOST study. He is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre. He chairs the Barts Health Gynae-oncology trials group. He is a member of the NCRI Ovarian Cancer Surgical Sub group and has a keen interest in ultra-radical debulking surgery for ovarian cancer. He leads the high-risk women’s precision prevention clinic at Barts Health and is chair of the London Cancer High risk gynaecological cancer MDT. He is a number of other advisory bodies and oversight committees. He is the Integrated Academic Training Programme Director and lead for the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London, London Specialty School of Obstetrics & Gynaecology. He has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011-2013.